VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (... (

VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial

Date:3/20/2008

- Top Line Data Is Expected to Be Presented in Third Quarter -

SAN FRANCISCO, March 20 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it has completed patient enrollment in its carotid endarterectomy (CEA) study, the first of three Phase 2 trials investigating VIA-2291, the company's lead product candidate.

VIA-2291 is a potent small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. It is being developed as a once-daily, oral drug to potentially decrease the risk of major adverse cardiac events associated with inflammation, including heart attack and stroke.

The CEA study enrolled 50 patients and is designed to provide direct evaluation of VIA-2291's effect on inflammation by analyzing plaque removed from the carotid arteries of patients treated with VIA-2291 or placebo. CEA is a surgical procedure to remove plaque from the carotid artery to increase blood flow to the brain in patients with significant blockage in the artery to reduce the risk of stroke. Patients who are diagnosed with carotid artery blockage are treated for three months with either VIA-2291 or placebo and then undergo a CEA procedure. The trial will also measure standard serum biomarkers of inflammation to measure reduction of inflammation in treated patients.

"Following analysis of the CEA study data, we expect to have important data with respect to VIA-2291's role in reducing vascular inflammation, as measured in the carotid plaque tissue," said Rebecca A. Taub, M.D., senior vice president of research and development of VIA Pharmaceuti
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate

Post Your Comments:

VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (...( - Top Line Data Is Expected to...),Health